DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Combipatch (Estradiol / Norethindrone Acetate) - Published Studies


Combipatch Related Published Studies

Well-designed clinical trials related to Combipatch (Estradiol / Norethindrone Transdermal)

Lipids and clotting factors during low dose transdermal estradiol/norethisterone use. [2005.04.11]

Effects of oral continuous and transdermal cyclic 17-beta estradiol and norethindrone acetate replacement therapy on platelet aggregation in postmenopausal women. [2002.08]

Positive effects on cardiovascular and breast metabolic markers of oral estradiol and dydrogesterone in comparison with transdermal estradiol and norethisterone acetate. [2002.04.25]

Low dose transdermal estradiol/norethisterone acetate treatment over 2 years does not cause endometrial proliferation in postmenopausal women. [2002.03]

Comparison between 1 year oral and transdermal oestradiol and sequential norethisterone acetate on circulating concentrations of leptin in postmenopausal women. [2001.08]

The effects of transdermal estradiol in combination with oral norethisterone on lipoproteins, coagulation, and endothelial markers in postmenopausal women with type 2 diabetes: a randomized, placebo-controlled study. [2001.03]

Failure of the combination of sequential oral and transdermal estradiol plus norethisterone acetate to affect plasma homocysteine levels. [2000.12]

Effects of oral and transdermal 17beta-estradiol with cyclical oral norethindrone acetate on insulin sensitivity, secretion, and elimination in postmenopausal women. [2000.06]

Lp(a) and lipids in adult Turner's syndrome: impact of treatment with 17beta-estradiol and norethisterone. [2000.05]

Efficacy of continuous sequential transdermal estradiol and norethindrone acetate in relieving vasomotor symptoms associated with menopause. [2000.01]

A randomized comparison of continuous combined transdermal delivery of estradiol-norethindrone acetate and estradiol alone for menopause. CombiPatch Study Group. [1999.10]

A randomised comparison of the effects of oral versus transdermal 17beta-oestradiol, each combined with sequential oral norethisterone acetate, on serum lipoprotein levels. [1999.09]

The effect of estradiol and a combined estradiol/progestagen preparation on insulin sensitivity in healthy postmenopausal women. [1999.07]

Hemodynamic effects of transdermal estradiol alone and combined with norethisterone acetate. [1997.06]

Transdermal sequential and continuous hormone replacement regimens with estradiol and norethisterone acetate in postmenopausal women: effects on the endometrium. [1997]

[Prevention of postmenopausal osteoporosis: how effective is transdermal hormone substitution? (Continuous estradiol plus sequential oral norethisterone acetate)] [1995.08.26]

Circulating nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17 beta-estradiol and norethisterone acetate. A two-year follow-up study. [1995.04]

Hormonal and metabolic effects of transdermal estradiol/progestagen administration in postmenopausal women. [1994.07]

Comparison of transdermal and oral sequential gestagen in combination with transdermal estradiol: effects on bleeding patterns and endometrial histology. [1993.11]

The optimal dose of oral norethindrone acetate for addition to transdermal estradiol: a multicenter study. [1990.03]

Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. [1989.09.23]

Well-designed clinical trials possibly related to Combipatch (Estradiol / Norethindrone Transdermal)

The effects of oral and transdermal hormone replacement therapy on C-reactive protein levels and other inflammatory markers in women with high risk of thrombosis. [2005.10.16]

Validation of the Women's Health Initiative Insomnia Rating Scale in a multicenter controlled clinical trial. [2005.01]

A comparison of the central effects of different progestins used in hormone replacement therapy. [2004.08.20]

Randomized trial of effect of transdermal continuous combined hormone replacement therapy on cardiovascular risk markers. [2004.03]

Comparison of the effect of oral and transdermal hormone therapy on fasting and postmethionine homocysteine levels. [2004.01]

[The effect of transdermal hormone replacement therapy on vasomotor symptoms in perimenopausal women] [2004]

Modulation by progestogens of the effects of oestrogen on hepatic endocrine function in postmenopausal women. [2003.12]

Effect of low-dose transdermal E2/NETA on the reduction of postmenopausal bone loss in women. [2003.05]

National differences in lipid response to postmenopausal hormone replacement therapy. [2002.08.30]

Impact of different hormone replacement therapy regimens on the size of myoma uteri in postmenopausal period: tibolone versus transdermal hormonal replacement system. [2002.07.25]

Pharmacokinetics of a new transdermal testosterone gel in gonadotrophin-suppressed normal men. [2002.05]

Effects of sequential combined transdermal and oral hormone replacement therapies on serum lipid and lipoproteins in postmenopausal women. [2002.01]

Glycaemic control and plasma lipoproteins in menopausal women with Type 2 diabetes treated with oral and transdermal combined hormone replacement therapy. [2001.12]

Effects of oral and transdermal hormone replacement therapy on internal carotid artery pulsatility indices in postmenopausal women. A prospective, randomized, comparative study. [2001.11]

Randomized comparison between orally and transdermally administered hormone replacement therapy regimens of long-term effects on 24-hour ambulatory blood pressure in postmenopausal women. [2001.04]

Postmenopause hormone treatment in women with NIDDM or impaired glucose tolerance: the MEDIA randomized clinical trial. [2000.12.29]

Plasma endothelin in postmenopausal women with type 2 diabetes mellitus and metabolic syndrome: a comparison of oral combined and transdermal oestrogen-only replacement therapy. [2000.10]

Administration of transdermal estrogen without progestin increases the capacity of plasma and serum to stimulate prostacyclin production in human vascular endothelial cells. [2000.01]

[Influence of hormone replacement therapy on the quality of life in postmenopausal women with hypertension] [2000]

Monofluorophosphate combined with hormone replacement therapy induces a synergistic effect on bone mass by dissociating bone formation and resorption in postmenopausal women: a randomized study. [1999.09]

Plasma oestrogen fractions in postmenopausal women receiving hormone replacement therapy: influence of route of administration and cigarette smoking. [1999.08]

Continuous, combined hormone replacement: randomized comparison of transdermal and oral preparations. [1999.07]

Randomized comparison of oral and transdermal hormone replacement on carotid and uterine artery resistance to blood flow. [1998.10]

Increased disorderliness and decreased mass and daily rate of endogenous growth hormone secretion in adult Turner syndrome: the impact of body composition, maximal oxygen uptake and treatment with sex hormones. [1998.08]

The long-term effects of oral and transdermal postmenopausal hormone replacement therapy on nitric oxide, endothelin-1, prostacyclin, and thromboxane. [1998.05]

Plasma insulin-like growth factor-I and its binding proteins 1 and 3 during continuous nonoral and oral combined hormone replacement therapy. [1998.01]

Continuous versus cyclical transdermal estrogen replacement therapy in postmenopausal women: influence on climacteric symptoms, body weight and bleeding pattern. [1997.12.15]

The effect of hormone replacement therapy on the oxidation of low density lipoprotein in postmenopausal women. [1997.11]

Responses of HDL subclasses, Lp(A-I) and Lp(A-I:A-II) levels and lipolytic enzyme activities to continuous oral estrogen-progestin and transdermal estrogen with cyclic progestin regimens in postmenopausal women. [1997.03.21]

Different effects of oral and transdermal hormonal replacement on prostacyclin and thromboxane A2. [1997.01]

Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids. [1997]

Effects of oral and transdermal oestrogen replacement therapy on plasma levels of insulin-like growth factors and IGF binding proteins 1 and 3: a cross-over study. [1996.12]

The antigonadotropic activity of progestins (19-nortestosterone and 19-norprogesterone derivatives) is not mediated through the androgen receptor. [1996.12]

Add-back therapy in the treatment of endometriosis: the European experience. [1996.10]

Hormone replacement therapy lowers plasma Lp(a) concentrations. Comparison of cyclic transdermal and continuous estrogen-progestin regimens. [1996.10]

Effects of postmenopausal estrogen/progestin replacement therapy on LDL particles; comparison of transdermal and oral treatment regimens. [1996.05]

Hormone replacement therapy reduces the reactivity of monocytes and platelets in whole blood--a beneficial effect on atherogenesis and thrombus formation? [1995.12]

Serum lipids and lipoproteins in postmenopausal women receiving transdermal oestrogen in combination with a levonorgestrel-releasing intrauterine device. [1995.06]

Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses. [1995.01]

Long-term effects of oral and transdermal hormone replacement therapies on serum lipid and lipoprotein concentrations. [1994.08]

Effects of hormone replacement therapy in rheumatoid arthritis: a double blind placebo-controlled study. [1994.01]

Insulin resistance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy. [1993.07]

Oral versus transdermal hormone replacement therapy. [1993]

Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on serum lipids and lipoproteins. [1992.03]

Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women. [1990.08.04]

Other research related to Combipatch (Estradiol / Norethindrone Transdermal)

Tibolone, transdermal estradiol or oral estrogen-progestin therapies: effects on circulating allopregnanolone, cortisol and dehydroepiandrosterone levels. [2005.03]

A multicenter, open-label study to evaluate satisfaction and menopausal quality of life in women using transdermal estradiol/norethindrone acetate therapy for the management of menopausal signs and symptoms. [2005]

The lipid and clinical effects of sequential transdermal estradiol and estradiol/norethisterone acetate in 674 women. [2003.10]

Impact of hormone replacement therapy on endogenous estradiol metabolism in postmenopausal women. [2002.10.25]

Effects of norethisterone acetate addition to estradiol in long term HRT. [2000.08.31]

Transdermal administration of estradiol and norethisterone: effect on the uterus and uterine arteries. [2000.03]

Visualization of percutaneous 3H-estradiol and 3H-norethindrone acetate transport across human epidermis as a function of time. [2000]

[Serum lipids in treatment with transdermal estradiol and oral norethisterone acetate] [1995.07]

Transdermal estradiol/norethisterone. A review of its pharmacological properties and clinical use in postmenopausal women. [1994.03]

Hormone replacement therapy by the transdermal administration of oestradiol and norethisterone. [1994.03]

Plasma lipid and lipoprotein effects of transdermal administration of estradiol and estradiol/norethisterone acetate. [1992.12.28]

Differential effects of transdermal estradiol and sequential progestogens on impedance to flow within the uterine arteries of postmenopausal women. [1992.11]

Endometrial effects of transdermal estradiol/norethisterone acetate. [1992.08]

Other possibly related research studies

Hormone replacement therapy and breast density changes. [2005.06]

Pharmaceutical development and clinical effectiveness of a novel gel technology for transdermal drug delivery. [2005.09]

Combined hormone therapy in postmenopausal women with features of metabolic syndrome. Results from a population-based study of Swedish women: Women's Health in the Lund Area study. [2004.09]

The effect of hormone replacement therapy on endothelial function in postmenopausal women with hypertension. [2004.02]

[Changes in bone density in hemodialysed women treated with transdermal hormone replacement therapy] [2003.09]

Hormone replacement therapy, C-reactive protein, and fibrinogen in healthy postmenopausal women. [2003.12.10]

Low-dose estrogen therapy for menopausal women: a review of efficacy and safety. [2003.10]

Impact of different progestins on endometrial vascularisation of postmenopausal women. A retrospective image analysis-morphometric study. [2003.11.20]

The short-term effects of different regimens of hormone replacement therapy on left ventricular structure and performance in healthy postmenopausal women. A prospective, controlled echocardiographic study. [2003]

The values of urinary NTx in postmenopausal women undergoing HRT; the role of additional alendronate therapy. [2002.08.30]

Hormone replacement therapy can augment vascular relaxation in post-menopausal women with type 2 diabetes. [2002.02]

Effects of HRT on serum levels of IGF-I in postmenopausal women. [2001.10.31]

Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. [2001.05]

HRT dosing regimens: continuous versus cyclic-pros and cons. [2001.01]

The insulin-like growth factor-I system and hormone replacement therapy. [2001.02]

[Basic principles of hormone replacement therapy in the postmenopause] [2000.10]

Effect of norethisterone acetate on estrogen metabolism in postmenopausal women. [2000.10]

Serum vascular endothelial growth factor concentrations in postmenopausal women: the effect of hormone replacement therapy. [2000.01]

Elevated levels of sE-selectin in post-menopausal females are decreased by hormone replacement therapy to levels observed in pre-menopausal females. [1999.11]

Reduced androgen levels in adult turner syndrome: influence of female sex steroids and growth hormone status. [1999.06]

Transvaginal ultrasonography and endometrial histology in peri- and postmenopausal women on hormone replacement therapy. [1999.05]

The influence of norethisterone acetate on urinary urodilatin excretion in postmenopausal women. [1998]

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017